BioHarvest Sciences secured its first-ever CDMO manufacturing and supply agreement for a rare premium fragrance, a milestone reached significantly ahead of schedule. The company revised its total 2026 revenue guidance downward to $37 million to $40 million from the previous $42 million to $48 million range, citing deliberate spending discipline in its direct-to-consumer business amid double-digit media inflation on platforms like Meta. Management now targets consolidated EBITDA breakeven in 2027 and projects the new fragrance agreement will generate $20 million to $30 million in revenue during the 2027-2028 time frame, with limited production starting in the first half of 2027. The company is shifting its strategy from proving the breadth of its Botanical Synthesis applications to selectively converting high-value opportunities into recurring manufacturing revenue and royalties, while reallocating capital from the D2C segment toward manufacturing capacity build-out and the growing CDMO division. BioHarvest also plans to launch single-dose VINIA Daily Chews in September 2026 and is developing a long-term licensing model for high-volume products like sweeteners, where partners build their own facilities and the company collects royalties.
BioHarvest Sciences Inc. Common StockCompany cuts 2026 revenue guidance, though secures first CDMO deal.
Meta Platforms Inc.
NVIDIA Corporation